Pembrolizumab plus chemotherapy in triple-negative breast cancer Reply

Cortes Javier; Rugo Hope S.; Guo Zifang; Karantza Vassiliki; Schmid Peter

首页> 外文期刊>The Lancet >Pembrolizumab plus chemotherapy in triple-negative breast cancer Reply

【24h】

Pembrolizumab plus chemotherapy in triple-negative breast cancer Reply

机译：Pembrolizumab加上三重阴性乳腺癌的化疗回复

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2021年第10294期|共3页
作者
Cortes Javier; Rugo Hope S.; Guo Zifang; Karantza Vassiliki; Schmid Peter;
展开▼
作者单位

Quiron Grp Int Breast Canc Ctr Madrid Spain;

Univ Calif San Francisco Ctr Comprehens Canc San Francisco CA 94143 USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Barts Canc Inst Ctr Expt Canc Med London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of dendritic cell/cytokine-induced killer cell immunobiological cancer therapy combined with adjuvant chemotherapy in patients with triple-negative breast cancer [J] . Ranran Zhang, Dongchu Ma, Xiaodong Xie, 中德临床肿瘤学杂志（英文版） . 2015,第001期
2. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy [J] . Yu-Ge Bai, Guo-Xuan Gao, Hong Zhang, 中华医学杂志（英文版） . 2020,第005期
3. Dose-dense paclitaxel plus carboplatin vs.epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer [J] . Qing Li, Ying Fan, Pin Zhang, 中国癌症研究（英文版） . 2020,第004期
4. Clinical Application of Lobaplatin Combined with Docetaxel in Adjuvant Chemotherapy for Triple-Negative Breast Cancer in Elderly Patients [J] . Weihua Jiang, Li Wang, Yongtao Li, 现代肿瘤学研究进展(英文) . 2020,第001期
5. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer [J] . Chengxiang Zhang, Binbin Deng, David W.McComb, 纳米研究（英文版） . 2019,第004期
6. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial [J] . Winer Eric P., Lipatov Oleg, Im Seock-Ah, The lancet oncology . 2021,第4期

机译：Pembrozumab与调查员选择化疗转移三重阴性乳腺癌（Keynote-119）：随机，开放标签，第3阶段试验
7. Pembrolizumab plus chemotherapy in triple-negative breast cancer [J] . Masuda Jun, Ozaki Yukinori, Hara Fumikata, The Lancet . 2021,第10294期

机译：Pembrolizumab加上三阴性乳腺癌化疗
8. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第5期

机译：Pembrolizumab加上化疗作为Neoadjuvant治疗高风险，早期三阴性乳腺癌：结果1B阶段开放标签，MulticoROGRENTENOTE-173研究
9. Optical coherence elastography as a new method for estimation of chemotherapy efficacy on triple-negative breast cancer in the experiment [C] . Anton A. Plekhanov, Marina A. Sirotkina, Alexander A. Sovetsky, International Symposium on Optics and Biophotonics: Saratov Fall Meeting . 2019

机译：光学相干弹性造影作为对实验中三阴性乳腺癌化疗疗效估算的新方法
10. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
11. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature [O] . Dongfeng Feng, Yaping Guan, Mingguo Liu, 2021

机译：在临床定义的超出以前在转移三重阴性乳腺癌治疗后临床定义过唑粒子后对atezolizumab的良好反应：案例报告和对文献的审查
12. 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia [O] . M. Md Yusof, D.W. Cescon, H.S. Rugo, 2020

机译：43O期III keynote-355对Pembrolizumab（Pembro）的研究Vs安慰剂（PbO）+化疗（Chemo）以前未经治疗的局部复发性或转移性三重阴性乳腺癌（TNBC）：患者（PTS）参加亚洲的结果
13. Targeting Nuclear FGF Receptor to Improve Chemotherapy Response in Triple-Negative Breast Cancer. [R] . Bachelder, R. E. 2014

机译：靶向核FGF受体改善三阴性乳腺癌化疗反应。

Pembrolizumab plus chemotherapy in triple-negative breast cancer Reply

著录项

相似文献

相关主题

期刊订阅